DBV Technologies | DBVT - Equity Capital And Reserves


DBV Technologies reported $52.85M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amarin USD 458.89M 6.03M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Insmed USD 945.57M 304.16M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 6.59B 583.4M Sep/2025